Listed

Relmada Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2017

Filed with the SEC on Nov 14, 2017 and accepted by EDGAR at Nov 14, 2017, 17:11 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2017-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2017-07-01 to 2017-09-30$165.8kus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2017-07-01 to 2017-09-30−$980.9kus-gaap:OperatingIncomeLoss
Net income3 months2017-07-01 to 2017-09-30−$981.7kus-gaap:NetIncomeLoss
Diluted EPS3 months2017-07-01 to 2017-09-30−$0.08us-gaap:EarningsPerShareBasicAndDiluted
Capital expenditure3 months2017-07-01 to 2017-09-30$2.6kus-gaap:PaymentsToAcquireProductiveAssets
Cash and equivalentsAt period end2017-09-30$4.7mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2017-09-30$5.3mus-gaap:AssetsCurrent
Total assetsAt period end2017-09-30$5.6mus-gaap:Assets
Current liabilitiesAt period end2017-09-30$3.5mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2017-09-30$4.1mus-gaap:Liabilities
Shareholders' equityAt period end2017-09-30$1.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001213900-17-012121. Last ingested by Listed: Nov 13, 2026, 15:42 ET. Listed shows no prices and gives no investment advice.